Please Wait.....
Report
Autologous Cell Therapy Market By Therapeutic area (Cancer, Others), By End user (Hospitals, Cancer treatment centers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-10-01 I 188 Pages I Allied Market Research
The global autologous cell therapy market was valued at $4,307.06 million in 2021, and is projected to reach $29,049.87 million by 2031, registering a CAGR of 21.0% from 2022 to 2031.
Autologous cell therapy is a novel therapeutic approach that is patient-specific and involves isolating & developing cells before reinfusing them back into the same person (for CAR-T cell therapy, isolated cells are genetically modified before reintroduction). Autologous cell therapy reduces the systemic immunological reactions, bio-incompatibility, and disease transmission hazards connected to grafts or cells that were not grown from the individual. It is used for treating various cancer, musculoskeletal, dermatological, neurodegenerative, & cardiac diseases, and others disorders.
The growth of global autologous cell therapy market is majorly driven by increase in demand for autologous cell therapy, owing to rise in R&D institutes & organizations for developing autologous cell therapy products and surge in chronic diseases especially cancer. For instance, in June 2020, FDA approved the product of Gilead Sciences Inc., Kite's Tecartus, an autologous CAR T-cell treatment for relapsed or refractory mantle cell lymphoma. In addition, rise in neurodegenerative disorders and upsurge in musculoskeletal disorders globally drive the market. Increasing emphasis on the replacement or regeneration of human cells, tissues, and organs to restore normal functionality to repair or replace cells in human tissues and organs that have undergone injury or illness and become damaged or dysfunctional further drives demand for autologous cell therapy and boosts the market growth. It can be accomplished by promoting the body's own cells to heal or by treating a patient with their own healthy cells.
Furthermore, automation in adult stem cells and cord blood processing & storage are the key technological advancements that fuel growth of the autologous cell therapy market. However, high cost and lower treatment facilities associated with autologous cell therapy may hinder the market growth. Conversely, high growth potential in untapped economies is anticipated to provide lucrative opportunities to the market players.
The autologous cell therapy market is segmented on the basis of therapeutic area, end user, and region. By therapeutic area, the market is bifurcated into cancer and others. The cancer segment is further categorized into lymphoma, acute lymphocytic leukemia, and others. On the basis of end user, the market is segregated into hospitals and cancer treatment centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
Major key players that operate in the autologous cell therapy market are Bristol Myers Squibb, CORESTEM, Inc., GC Biopharma Corp (GC Cell), Gilead Sciences, Inc. (Kite Pharma, Inc.), Holostem Terapie Avanzate S.r.l., Johnson & Johnson Private Limited (Janssen Biotech, Inc), Novartis AG, Sanpower Group (Dendreon Pharmaceuticals LLC.), Tego Science, and Vericel Corporation.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autologous cell therapy market analysis from 2021 to 2031 to identify the prevailing autologous cell therapy market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the autologous cell therapy market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global autologous cell therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapeutic area
- Others
- Cancer
- Type
- Lymphoma
- Acute lymphocytic leukemia
- Others
By End user
- Hospitals
- Cancer treatment centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
- Key Market Players
- Bristol Myers Squibb
- Novartis
- Vericel Corporation
- Gilead Sciences (Kite Pharma, Inc.)
- Johnson & Johnson(Janssen Biotech, Inc)
- Tego Science
- Sanpower Group (Dendreon Pharmaceuticals LLC.)
- Holostem Terapie Avanzate S.r.l.
- GC Biopharma (GC Cell)
- CORESTEM, Inc
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA
4.1 Overview
4.1.1 Market size and forecast
4.2 Cancer
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.2.4 Cancer Autologous Cell Therapy Market by Type
4.3 Others
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: AUTOLOGOUS CELL THERAPY MARKET, BY END USER
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Cancer treatment centers
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: AUTOLOGOUS CELL THERAPY MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapeutic area
6.2.3 North America Market size and forecast, by End user
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Therapeutic area
6.2.4.1.3 Market size and forecast, by End user
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Therapeutic area
6.2.4.2.3 Market size and forecast, by End user
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Therapeutic area
6.2.4.3.3 Market size and forecast, by End user
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapeutic area
6.3.3 Europe Market size and forecast, by End user
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Therapeutic area
6.3.4.1.3 Market size and forecast, by End user
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Therapeutic area
6.3.4.2.3 Market size and forecast, by End user
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Therapeutic area
6.3.4.3.3 Market size and forecast, by End user
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Therapeutic area
6.3.4.4.3 Market size and forecast, by End user
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Therapeutic area
6.3.4.5.3 Market size and forecast, by End user
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Therapeutic area
6.3.4.6.3 Market size and forecast, by End user
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapeutic area
6.4.3 Asia-Pacific Market size and forecast, by End user
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Therapeutic area
6.4.4.1.3 Market size and forecast, by End user
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Therapeutic area
6.4.4.2.3 Market size and forecast, by End user
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Therapeutic area
6.4.4.3.3 Market size and forecast, by End user
6.4.4.4 Australia
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Therapeutic area
6.4.4.4.3 Market size and forecast, by End user
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Therapeutic area
6.4.4.5.3 Market size and forecast, by End user
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Therapeutic area
6.4.4.6.3 Market size and forecast, by End user
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapeutic area
6.5.3 LAMEA Market size and forecast, by End user
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Latin America
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Therapeutic area
6.5.4.1.3 Market size and forecast, by End user
6.5.4.2 Middle East And Africa
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Therapeutic area
6.5.4.2.3 Market size and forecast, by End user
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Bristol Myers Squibb
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Novartis
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Vericel Corporation
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Gilead Sciences (Kite Pharma, Inc.)
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Johnson & Johnson(Janssen Biotech, Inc)
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Tego Science
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Sanpower Group (Dendreon Pharmaceuticals LLC.)
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Holostem Terapie Avanzate S.r.l.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 GC Biopharma (GC Cell)
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 CORESTEM, Inc
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 2. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL CANCER AUTOLOGOUS CELL THERAPY MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 5. AUTOLOGOUS CELL THERAPY MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. AUTOLOGOUS CELL THERAPY MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 8. AUTOLOGOUS CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. AUTOLOGOUS CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. AUTOLOGOUS CELL THERAPY MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. U.S. AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 17. U.S. AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 18. CANADA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 19. CANADA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 20. MEXICO AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 21. MEXICO AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 22. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 23. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 24. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. GERMANY AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 26. GERMANY AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 27. FRANCE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 28. FRANCE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 29. UK AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 30. UK AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 31. ITALY AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 32. ITALY AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 33. SPAIN AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 34. SPAIN AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 35. REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 36. REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 38. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 39. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. JAPAN AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 41. JAPAN AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. CHINA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 43. CHINA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 44. INDIA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 45. INDIA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 47. AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 48. SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 49. SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 50. REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 51. REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 52. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 53. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 54. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 55. LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 56. LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 57. MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
TABLE 58. MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 60.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
TABLE 61.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 62.BRISTOL MYERS SQUIBB: NET SALES
TABLE 63.BRISTOL MYERS SQUIBB: KEY STRATERGIES
TABLE 64.NOVARTIS: COMPANY SNAPSHOT
TABLE 65.NOVARTIS: OPERATING SEGMENTS
TABLE 66.NOVARTIS: PRODUCT PORTFOLIO
TABLE 67.NOVARTIS: NET SALES
TABLE 68.NOVARTIS: KEY STRATERGIES
TABLE 69.VERICEL CORPORATION: COMPANY SNAPSHOT
TABLE 70.VERICEL CORPORATION: OPERATING SEGMENTS
TABLE 71.VERICEL CORPORATION: PRODUCT PORTFOLIO
TABLE 72.VERICEL CORPORATION: NET SALES
TABLE 73.VERICEL CORPORATION: KEY STRATERGIES
TABLE 74.GILEAD SCIENCES (KITE PHARMA, INC.): COMPANY SNAPSHOT
TABLE 75.GILEAD SCIENCES (KITE PHARMA, INC.): OPERATING SEGMENTS
TABLE 76.GILEAD SCIENCES (KITE PHARMA, INC.): PRODUCT PORTFOLIO
TABLE 77.GILEAD SCIENCES (KITE PHARMA, INC.): NET SALES
TABLE 78.GILEAD SCIENCES (KITE PHARMA, INC.): KEY STRATERGIES
TABLE 79.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): COMPANY SNAPSHOT
TABLE 80.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): OPERATING SEGMENTS
TABLE 81.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): PRODUCT PORTFOLIO
TABLE 82.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): NET SALES
TABLE 83.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): KEY STRATERGIES
TABLE 84.TEGO SCIENCE: COMPANY SNAPSHOT
TABLE 85.TEGO SCIENCE: OPERATING SEGMENTS
TABLE 86.TEGO SCIENCE: PRODUCT PORTFOLIO
TABLE 87.TEGO SCIENCE: NET SALES
TABLE 88.TEGO SCIENCE: KEY STRATERGIES
TABLE 89.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): COMPANY SNAPSHOT
TABLE 90.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): OPERATING SEGMENTS
TABLE 91.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): PRODUCT PORTFOLIO
TABLE 92.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): NET SALES
TABLE 93.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): KEY STRATERGIES
TABLE 94.HOLOSTEM TERAPIE AVANZATE S.R.L.: COMPANY SNAPSHOT
TABLE 95.HOLOSTEM TERAPIE AVANZATE S.R.L.: OPERATING SEGMENTS
TABLE 96.HOLOSTEM TERAPIE AVANZATE S.R.L.: PRODUCT PORTFOLIO
TABLE 97.HOLOSTEM TERAPIE AVANZATE S.R.L.: NET SALES
TABLE 98.HOLOSTEM TERAPIE AVANZATE S.R.L.: KEY STRATERGIES
TABLE 99.GC BIOPHARMA (GC CELL): COMPANY SNAPSHOT
TABLE 100.GC BIOPHARMA (GC CELL): OPERATING SEGMENTS
TABLE 101.GC BIOPHARMA (GC CELL): PRODUCT PORTFOLIO
TABLE 102.GC BIOPHARMA (GC CELL): NET SALES
TABLE 103.GC BIOPHARMA (GC CELL): KEY STRATERGIES
TABLE 104.CORESTEM, INC: COMPANY SNAPSHOT
TABLE 105.CORESTEM, INC: OPERATING SEGMENTS
TABLE 106.CORESTEM, INC: PRODUCT PORTFOLIO
TABLE 107.CORESTEM, INC: NET SALES
TABLE 108.CORESTEM, INC: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.AUTOLOGOUS CELL THERAPY MARKET SEGMENTATION
FIGURE 2.AUTOLOGOUS CELL THERAPY MARKET,2021-2031
FIGURE 3.AUTOLOGOUS CELL THERAPY MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.AUTOLOGOUS CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.AUTOLOGOUS CELL THERAPY MARKET,BY THERAPEUTIC AREA,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CANCER AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OTHERS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)
FIGURE 15.AUTOLOGOUS CELL THERAPY MARKET,BY END USER,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CANCER TREATMENT CENTERS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)
FIGURE 18.AUTOLOGOUS CELL THERAPY MARKET BY REGION,2021
FIGURE 19.U.S. AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 20.CANADA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 21.MEXICO AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 22.GERMANY AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 23.FRANCE AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 24.UK AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 25.ITALY AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 26.SPAIN AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 27.REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 28.JAPAN AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 29.CHINA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 30.INDIA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 31.AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 32.SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 33.REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 34.LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 35.MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40.COMPETITIVE DASHBOARD
FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 42.BRISTOL MYERS SQUIBB.: NET SALES ($MILLION)
FIGURE 43.NOVARTIS.: NET SALES ($MILLION)
FIGURE 44.VERICEL CORPORATION.: NET SALES ($MILLION)
FIGURE 45.GILEAD SCIENCES (KITE PHARMA, INC.).: NET SALES ($MILLION)
FIGURE 46.JOHNSON & JOHNSON(JANSSEN BIOTECH, INC).: NET SALES ($MILLION)
FIGURE 47.TEGO SCIENCE.: NET SALES ($MILLION)
FIGURE 48.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.).: NET SALES ($MILLION)
FIGURE 49.HOLOSTEM TERAPIE AVANZATE S.R.L..: NET SALES ($MILLION)
FIGURE 50.GC BIOPHARMA (GC CELL).: NET SALES ($MILLION)
FIGURE 51.CORESTEM, INC.: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security